HOOKE

HOOKE represents the genomics-forward frontier of longevity medicine in London, offering whole-genome sequencing and polygenic risk scoring as standard components of their proprietary BioPortrait assessment. The Mayfair location provides an ultra-premium patient experience, and the team's data analytics approach to longitudinal health tracking reflects a genuine commitment to turning genetic insights into actionable health strategies. The BioPortrait framework aims to create a uniquely detailed biological profile for each patient, going beyond standard biomarker panels to incorporate genomic, epigenetic, and metabolic dimensions. The focus on making genetics clinically actionable, rather than just informational, distinguishes HOOKE from competitors who include genomics as an optional add-on. As a 2023 launch with a small team, HOOKE is still building its operational track record and long-term patient outcome data. The offering is heavily diagnostic, with limited therapeutic pathways available in-house. The GBP 8,000-25,000 annual membership represents a significant commitment, particularly for a clinic in its early years. For data-driven London professionals who want genomics at the center of their longevity strategy and are comfortable as early adopters of a promising new model, HOOKE offers a distinctive and intellectually rigorous approach.